Evidence map›Paper›PMID 27809484›Full record

ArticleAnalytical chemistry2016

Characterizing Protein Glycosylation through On-Chip Glycan Modification and Probing.

Bryan S Reatini, Elliot Ensink, Brian Liau, Jessica Y Sinha, Thomas W Powers, Katie Partyka, Marshall Bern, Randall E Brand, Pauline M Rudd, Doron Kletter and 2 more

Open access · greenAbstract read
In one paragraph

Article in Analytical chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Bryan S ReatiniVan Andel Research Institute , Grand Rapids, Michigan 49503, United States.
Elliot EnsinkVan Andel Research Institute , Grand Rapids, Michigan 49503, United States.
Brian LiauBioprocessing Technology Institute , 138668, Singapore.
Jessica Y SinhaVan Andel Research Institute , Grand Rapids, Michigan 49503, United States.
Thomas W PowersMedical University of South Carolina , Charleston, South Carolina 29425, United States.
Katie PartykaVan Andel Research Institute , Grand Rapids, Michigan 49503, United States.
Marshall BernProtein Metrics, Inc. , San Carlos, California 94070, United States.
Randall E BrandUniversity of Pittsburgh Medical Center , Pittsburgh, Pennsylvania 15237, United States.
Pauline M RuddBioprocessing Technology Institute , 138668, Singapore.
Doron KletterProtein Metrics, Inc. , San Carlos, California 94070, United States.
Richard DrakeProtein Metrics, Inc. , San Carlos, California 94070, United States.
Brian B HaabVan Andel Research Institute , Grand Rapids, Michigan 49503, United States.
Van Andel Institute · USProtein Metrics (United States) · USBioprocessing Technology Institute · SGMedical University of South Carolina · USUniversity of Pittsburgh Medical Center · US

Funding

Detection of Pre-Invasive Pancreatic Cysts Using Protein and Glycan BiomarkersU01CA152653 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI ALLEN, PETER J, BRAND, RANDALL · 2010 to 2021
$5.8M
Targeted Glycomics and Affinity Reagents for Cancer Biomarker DevelopmentU01CA168896 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI HAAB, BRIAN B. · 2012 to 2016
$2.3M
Comprehensive Glycoproteomic Tool Development for Cancer BiomarkersR41GM112750 · NIGMS · PROTEIN METRICS, LLC · PI BECKER, CHRISTOPHER H, HAAB, BRIAN B. · 2014 to 2015
$686k
On-chip Glycan Analysis of Clinical SpecimensR21AI129872 · NIAID · VAN ANDEL RESEARCH INSTITUTE · PI HAAB, BRIAN B. · 2016 to 2017
$631k
Direct Tumor Glycan Profiling on Tissue MicroarraysR21CA186799 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DRAKE, RICHARD R. · 2015 to 2016
$496k
NCI NIH HHS R21 CA186799NCI NIH HHS U01 CA152653NCI NIH HHS U01 CA168896NIAID NIH HHS R21 AI129872NIGMS NIH HHS R41 GM112750
6 · The paper itself

Abstract

Glycans are critical to protein biology and are useful as disease biomarkers. Many studies of glycans rely on clinical specimens, but the low amount of sample available for some specimens limits the experimental options. Here we present a method to obtain information about protein glycosylation using a minimal amount of protein. We treat proteins that were captured or directly spotted in small microarrays (2.2 mm × 2.2 mm) with exoglycosidases to successively expose underlying features, and then we probe the native or exposed features using a panel of lectins or glycan-binding reagents. We developed an algorithm to interpret the data and provide predictions about the glycan motifs that are present in the sample. We demonstrated the efficacy of the method to characterize differences between glycoproteins in their sialic acid linkages and N-linked glycan branching, and we validated the assignments by comparing results from mass spectrometry and chromatography. The amount of protein used on-chip was about 11 ng. The method also proved effective for analyzing the glycosylation of a cancer biomarker in human plasma, MUC5AC, using only 20 μL of the plasma. A glycan on MUC5AC that is associated with cancer had mostly 2,3-linked sialic acid, whereas other glycans on MUC5AC had a 2,6 linkage of sialic acid. The on-chip glycan modification and probing (on-chip GMAP) method provides a platform for analyzing protein glycosylation in clinical specimens and could complement the existing toolkit for studying glycosylation in disease.

Indexed as

AlgorithmsGlycosylationHumansMicroarray AnalysisMucin 5ACPolysaccharidesSoftwareMUC5AC protein, humanMucin 5ACPolysaccharides

Identifiers

PMID27809484
PMCPMC5290727
OpenAlexW2547330171

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.